Stoke Therapeutics Plunges 12.58% Amid CEO Departure

On April 11, 2025, Stoke Therapeutics experienced a significant drop of 12.58% in pre-market trading, reflecting a notable shift in investor sentiment towards the biotechnology company.

Stoke Therapeutics has not yet confirmed its next earnings publication date, but it is estimated to be on Monday, May 5th, 2025. This anticipation of earnings reports often influences stock prices as investors speculate on the company's financial performance.

In a recent development, Stoke Therapeutics reported a Q4 loss but managed to exceed revenue estimates, indicating a mixed financial performance. Additionally, the company announced that its CEO, Edward Kaye, will be stepping down, which could be a significant factor in the recent stock price movement.

Despite the recent drop, analysts maintain a strong buy rating for Stoke Therapeutics, with an average price target that suggests a substantial upside from current levels. This optimistic outlook from analysts may provide some support for the stock in the coming days.